The investment marks a strategic alignment between the California-based biotech and the South Korean conglomerate. GRAIL plans to use the capital to extend its cash runway as it navigates the regulatory hurdles required to secure reimbursement for its Galleri multi-cancer early detection test in the United States. Beyond domestic priorities, the funding serves as a vehicle for a broader regional partnership.

GRAIL and Samsung C&T intend to collaborate on introducing the Galleri test to South Korea, with potential expansion into Japan and Singapore. While the business development efforts are global, initial laboratory processing for the screening technology will remain consolidated at the company’s facility in Research Triangle Park, North Carolina. For Samsung, the move represents a deeper commitment to the life sciences sector, integrating advanced diagnostic tools into their existing portfolio of biopharmaceutical interests.